HelixNano
Cambridge
About HelixNano
Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re already testing COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $59.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2024)
- Website: helixnano.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/helixnano-73084 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.